Q3 2024 Earnings Call Transcript November 4, 2024 Zoetis Inc. beats earnings expectations. Reported EPS is $1.58, ...

Simparica Trio became the number one vet-prescribed parasiticide, with over 13 million dogs treated, highlighting its market ...

Simparica Trio became the number one vet-prescribed parasiticide, with over 13 million dogs treated, highlighting its market leadership. Zoetis Inc (NYSE:ZTS) successfully divested its medicated ...

particularly Simparica Trio, has seen robust growth and market expansion. The dermatology portfolio, led by Apoquel, continues to lead in prescriptions. Zoetis maintains a strong product pipeline ...

3. Parasiticides: Products like Simparica Trio continue to contribute to Zoetis's growth in the companion animal segment. 4. Pipeline Products: Zoetis is developing a promising next-generation ...

The Simparica franchise, particularly Simparica Trio, has seen robust growth and market expansion. The dermatology portfolio, led by Apoquel, continues to lead in prescriptions. Zoetis maintains a ...

3. Parasiticides: Products like Simparica Trio continue to contribute to Zoetis's growth in the companion animal segment. 4. Pipeline Products: Zoetis is developing a promising next-generation ...

Zoetis saw notable growth in both companion animal and livestock segments.

Zoetis smashes Q3 estimates, raises full-year guidance, and makes bold moves to dominate animal health innovation ...